WuXi PharmaTech has a contract manufacturing agreement with TaiMed Biologics for the manufacture of ibalizumab (TMB-355) in support of Phase II and Phase III clinical trials globally. Ibalizumab is a humanized monoclonal antibody and a member of an emerging class of HIV therapies known as viral-entry inhibitors.  This work will be completed at WuXi’s biologics manufacturing facilities in China and its biologics testing facilities in the U.S. “We are pleased that TaiMed Biologics has...